Canaccord raised the firm’s price target on AxoGen (AXGN) to $26 from $22 and keeps a Buy rating on the shares. The firm said they posted strong Q4 results as the company notes its positive performance reflects ongoing improvements in commercial execution, including its focus on high-potential accounts along with adoption of AXGN’s algorithm across procedures.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXGN: